CordovaCann Corp (LVRLF) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of CordovaCann Corp $0.09, price $0.02, upside +370.0%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch CordovaCann Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $0.0100 – $0.3840 · fair‑value band $0.0628 – $0.1369 · the $0.0200 price screens below the $0.0940 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow CordovaCann in your weekly email
Every Wednesday you see whether CordovaCann is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
CordovaCann Corp. engages in the provision of services and investment capital to the processing, production, and retail vertical markets of the cannabis industry in Canada and United States. The company was formerly known as LiveReel Media Corporation and changed its name to CordovaCann Corp. in January 2018. CordovaCann Corp.
Show more
CordovaCann Corp. engages in the provision of services and investment capital to the processing, production, and retail vertical markets of the cannabis industry in Canada and United States. The company was formerly known as LiveReel Media Corporation and changed its name to CordovaCann Corp. in January 2018. CordovaCann Corp. was founded in 1997 and is headquartered in Toronto, Canada.
Stock analysis
CordovaCann Corp (LVRLF) currently trades at $0.0200, while our model-based Fair Value estimate is $0.0940, implying the stock looks roughly 78.7% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $0.2600 per share, and 9 of the 9 models we run sit above the $0.0200 price.
Bear case: the Multiples group reads lowest at $0.0800, and 0 of the 9 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.0628 (bear) to $0.1369 (bull), the price of $0.0200 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
CordovaCann Corp reported revenue of C$14.2M in FY2025 versus C$10.3M in FY2021, a compound +8.4%/yr. Reported net income was −C$2.7M in FY2025.
Key figures
Market cap $3.6M · P/S ratio 0.26 · EPS (TTM) $−0.0100 · Net margin −18.9% · Return on equity −531% · Return on assets (EBIT) −14.2% · Operating margin 4.5% · Revenue (TTM) C$13.7M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 71% below its 52-week high and 100% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 370%, LVRLF screens cheaper than that median.
Fair Value models
Bear $0.0628Fair Value $0.0940Bull $0.1369
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.50/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+3.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+143.4%
Start year 2020 (pandemic)
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+48.8%
’05
’06
’07
’08
’09
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,094.0% (2020) → −1.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−14.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CAD, Canada: IMF forecast 2.1% a year to 2030, 2.6% from 2016 to 2025) that is about −16.1% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks
Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside+200% · Top 25%
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets4% · Above median
Net margin (TTM)−19% · Bottom 25%
Operating margin (TTM)4% · Below median
Growth and dividend
Revenue growth−10% · Bottom 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM)0.26× · Cheapest 25%
P/FCF3.2× · Pricier than median
EV/EBITDA6.0× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)100· sector 15
FUTURE (revenue growth)0· sector 20
PAST (return on equity)0· sector 27
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 32
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "CordovaCann Corp Fair Value". https://www.fairvalue-calculator.com/stock/LVRLF
Frequently asked questions
Is CordovaCann Corp (LVRLF) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.0940 versus a price of $0.0200, about +370% upside (undervalued).
What is the fair value of LVRLF?
Our model-based fair value for CordovaCann Corp is $0.0940 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.0200.
What is the quality score of LVRLF?
CordovaCann Corp has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CordovaCann Corp (LVRLF)?
Our model-based price target is the fair value of $0.0940 (as of Sep 23, 2026) from 9 valuation models. Cautious scenario $0.0628, optimistic scenario $0.1369. It is a calculation from audited fundamentals, not an analyst target.
What is the CordovaCann Corp stock forecast for 2026?
Our models put fair value at $0.0940, about +370% upside versus a price of $0.0200 (undervalued). Cautious scenario $0.0628, optimistic scenario $0.1369. The calculation is refreshed regularly with new filings.
What is the revenue of CordovaCann Corp (LVRLF)?
CordovaCann Corp reported trailing-twelve-month revenue of about C$13.7M (latest available figure, as of Sep 23, 2026).
What growth is priced into CordovaCann Corp (LVRLF)?
For today's price to be fair in a discounted-cash-flow model, CordovaCann Corp would have to grow free cash flow by -14.4 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +143.4 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of LVRLF use?
Our models discount CordovaCann Corp at 9.7 %: a base by market capitalisation (nano), country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For CordovaCann Corp that is -14.4 % per year a year over ten years, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has CordovaCann Corp (LVRLF) delivered so far?
Over the past 5 years revenue at CordovaCann Corp grew +143.4 % a year. The price currently implies -14.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of CordovaCann Corp (LVRLF) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into CordovaCann Corp (-14.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of CordovaCann Corp (LVRLF)?
The free-cash-flow yield on the price is 36.17 %: that much free cash flow CordovaCann Corp produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of CordovaCann Corp (LVRLF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CordovaCann Corp it is $0.0940 per share (as of Sep 23, 2026), against a price of $0.0200. It is the blended result of 9 valuation models (cash flow, earnings, asset, dividend).
Is CordovaCann Corp stock overvalued or undervalued in 2026?
As of Sep 23, 2026, LVRLF trades below its calculated fair value: price $0.0200, fair value $0.0940, a gap of about +370% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LVRLF?
No. The price is what the market pays today ($0.0200); the fair value is what the company's own numbers justify ($0.0940). For CordovaCann Corp the two are $0.0740 per share apart. That gap is exactly why we show both numbers side by side.
How much is CordovaCann Corp worth?
The market values CordovaCann Corp at about $3.6M (market capitalisation, as of Sep 23, 2026). Per share that is $0.0200; our models calculate a fair value of $0.0940 per share.
What do the bullish and bearish scenarios say about LVRLF?
Our models span a range for CordovaCann Corp: cautious scenario $0.0628, base $0.0940, optimistic $0.1369 per share (as of Sep 23, 2026, price $0.0200). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CordovaCann Corp (LVRLF)?
Balance-sheet figures for CordovaCann Corp (as of Sep 23, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is LVRLF from its 52-week high?
CordovaCann Corp trades at $0.0200, about 71% below its 52-week high of $0.0700 and 100% above the low of $0.0100 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0940 is for.
Which stocks are comparable to CordovaCann Corp?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CordovaCann Corp stock attractive at the current price?
The data as of Sep 23, 2026: price $0.0200, calculated fair value $0.0940 (+370%), Quality Score 52/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LVRLF calculated?
We run CordovaCann Corp through 9 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0940, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. CordovaCann Corp currently trades 370 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CordovaCann Corp (LVRLF)?
The closing price on Sep 24, 2026 was $0.0200. Our model-based fair value is $0.0940, about +370% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CordovaCann Corp right now?
The price is below even our cautious bear case ($0.0628). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (52/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($0.0628 to $0.1369) leaves room in how you read the outcome.
Key figures of CordovaCann Corp
How large is the market capitalisation of CordovaCann Corp (LVRLF)?
The market capitalisation of CordovaCann Corp is $3.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CordovaCann Corp (LVRLF)?
The price-to-sales ratio of CordovaCann Corp is 0.26 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CordovaCann Corp (LVRLF)?
Earnings per share at CordovaCann Corp are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of CordovaCann Corp (LVRLF)?
The net margin of CordovaCann Corp is −18.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CordovaCann Corp (LVRLF)?
The return on equity (ROE) of CordovaCann Corp is −531% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CordovaCann Corp (LVRLF)?
On an EBIT basis the return on assets of CordovaCann Corp is −14.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CordovaCann Corp (LVRLF)?
The operating margin of CordovaCann Corp is 4.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CordovaCann Corp (LVRLF)?
Revenue at CordovaCann Corp is growing −9.9% versus a year earlier (3y avg +1.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does CordovaCann Corp (LVRLF) carry?
The net debt of CordovaCann Corp is C$1.6M (fiscal year 2025, ≈ 1.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch CordovaCann Corp in the live analysis
One click puts CordovaCann Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026